Bank of New York Mellon’s Clovis Oncology, Inc. CLVS Stock Holding History

Bank of New York Mellon’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-97,995	Closed	-$117K	–	4595
2022 Q3	$117K	Buy	97,995 +27,477	+39%	+$42.8K	﹤0.01%	4169
2022 Q2	$127K	Sell	70,518 -300,778	-81%	-$444K	﹤0.01%	4183
2022 Q1	$750K	Buy	371,296 +2,635	+0.7%	+$5.18K	﹤0.01%	3482
2021 Q4	$999K	Sell	368,661 -8,635	-2%	-$31.9K	﹤0.01%	3389
2021 Q3	$1.68M	Buy	377,296 +77,023	+26%	+$371K	﹤0.01%	3094
2021 Q2	$1.74M	Sell	300,273 -40,983	-12%	-$240K	﹤0.01%	3082
2021 Q1	$2.4M	Sell	341,256 -82,281	-19%	-$552K	﹤0.01%	2828
2020 Q4	$2.03M	Buy	423,537 +53,884	+15%	+$273K	﹤0.01%	2836
2020 Q3	$2.15M	Buy	369,653 +28,332	+8%	+$170K	﹤0.01%	2627
2020 Q2	$2.3M	Buy	341,321 +58,179	+21%	+$441K	﹤0.01%	2597
2020 Q1	$1.8M	Buy	283,142 +84,946	+43%	+$681K	﹤0.01%	2606
2019 Q4	$2.07M	Sell	198,196 -936	-0.5%	-$6.81K	﹤0.01%	2801
2019 Q3	$783K	Sell	199,132 -25,881	-12%	-$209K	﹤0.01%	3302
2019 Q2	$3.35M	Sell	225,013 -29,247	-12%	-$528K	﹤0.01%	2529
2019 Q1	$6.31M	Buy	254,260 +11,558	+5%	+$290K	﹤0.01%	2222
2018 Q4	$4.36M	Buy	242,702 +12,205	+5%	+$249K	﹤0.01%	2381
2018 Q3	$6.77M	Sell	230,497 -12,964	-5%	-$502K	﹤0.01%	2251
2018 Q2	$11.1M	Sell	243,461 -11,998	-5%	-$584K	﹤0.01%	1965
2018 Q1	$13.5M	Buy	255,459 +3,657	+1%	+$213K	﹤0.01%	1827
2017 Q4	$17.1M	Sell	251,802 -23,524	-9%	-$1.64M	﹤0.01%	1669
2017 Q3	$22.7M	Sell	275,326 -458,520	-62%	-$36.3M	0.01%	1486
2017 Q2	$68.7M	Buy	733,846 +489,025	+200%	+$29.9M	0.02%	772
2017 Q1	$15.6M	Buy	244,821 +70,539	+40%	+$4.29M	﹤0.01%	1698
2016 Q4	$7.74M	Buy	174,282 +255	+0.1%	+$8.97K	﹤0.01%	2097
2016 Q3	$6.27M	Buy	174,027 +9,292	+6%	+$199K	﹤0.01%	2130
2016 Q2	$2.26M	Buy	164,735 +12,305	+8%	+$180K	﹤0.01%	2637
2016 Q1	$2.93M	Sell	152,430 -5,726	-4%	-$121K	﹤0.01%	2445
2015 Q4	$5.54M	Sell	158,156 -27,895	-15%	-$1.8M	﹤0.01%	2152
2015 Q3	$17.1M	Buy	186,051 +1,304	+0.7%	+$113K	0.01%	1514
2015 Q2	$16.2M	Buy	184,747 +24,009	+15%	+$2.06M	﹤0.01%	1622
2015 Q1	$11.9M	Buy	160,738 +9,603	+6%	+$678K	﹤0.01%	1859
2014 Q4	$8.46M	Buy	151,135 +13,038	+9%	+$685K	﹤0.01%	2009
2014 Q3	$6.26M	Buy	138,097 +5,151	+4%	+$215K	﹤0.01%	2170
2014 Q2	$5.51M	Buy	132,946 +14,963	+13%	+$771K	﹤0.01%	2276
2014 Q1	$8.17M	Buy	117,983 +14,680	+14%	+$1.08M	﹤0.01%	2025
2013 Q4	$6.23M	Buy	103,303 +22,507	+28%	+$1.22M	﹤0.01%	2164
2013 Q3	$4.91M	Sell	80,796 -2,068	-2%	-$147K	﹤0.01%	2263
2013 Q2	$5.55M	Buy	+82,864	New	+$3.73M	﹤0.01%	2125

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Bank of New York Mellon's CLVS Position: Q4 2022 in Review

Bank of New York Mellon sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 97,995 shares — an estimated $117K sold.

Bank of New York Mellon first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $68.7M in Q2 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Bank of New York Mellon reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Bank of New York Mellon sold 97,995 Clovis Oncology, Inc. shares in Q4 2022, an estimated $117K.
Bank of New York Mellon first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
Bank of New York Mellon's Clovis Oncology, Inc. position peaked at $68.7M in Q2 2017.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.